Cytori Therapeutics, Inc. announced that on July 5, 2019, Gary Titus notified the Company of his intention to resign from his position as Chief Financial Officer and Secretary. He will remain with the Company in a part time role as an advisor. His resignation as Chief Financial Officer and Secretary and transition to a part time advisory role will be effective immediately.

Mr. Titus' departure as Chief Financial Officer is not due to a dispute or disagreement with the Company or the Company's auditors. On July 5, 2019, the board of directors of the Company approved the appointment of Alan Lins to succeed Mr. Titus as the Company's Vice President of Finance and Controller and Mr. Lins will serve as the Company's principal financial and accounting officer effective immediately. Alan Lins joined as Corporate Controller and Director of Finance in July 2015.

Mr. Lins joined from Graham Holdings, Inc., where he last served as Corporate Audit Sr. Manager from October 2013 to June 2015. Prior to joining Graham Holdings, Inc., Mr. Lins served as Senior Manager, Assurance at Ernst & Young, LLP for over 15 years. Mr. Lins is a certified public accountant with over 25 years' experience in the accounting and finance.